226 results about "High glucose" patented technology

The invention discloses a blood glucose concentration prediction method combined with a neural network, and relates to the technical field of blood glucose concentration prediction.The method comprises the steps that continuous blood glucose monitoring equipment interacts with a target user to conduct blood glucose monitoring, and a dynamic blood glucose concentration sequence in a preset monitoring window is extracted; acquiring an exercise data set, a food intake data set, an insulin use record set and an environment monitoring data set of the target user in the preset monitoring window; obtaining a blood glucose data topological framework sequence; obtaining a blood glucose feature recognition model; performing cross-scale mapping interaction analysis to obtain blood glucose associated features; training a blood glucose concentration prediction network layer; and performing blood sugar concentration prediction on the blood sugar related characteristics to obtain a blood sugar concentration prediction result. The technical problem that in the prior art, blood glucose concentration prediction is conducted in a single dimension, and the accuracy of the prediction result is low is solved, and the technical effect of improving the accuracy and timeliness of blood glucose concentration prediction is achieved.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of a Pucurbita pepo polypeptide Nacrein-LP20 in preparation of a medicine for promoting wound healing and a preparation method of the Pucurbita pepo polypeptide Nacrein-LP20. The amino acid sequence of the Hepu pearl polypeptide Nacrein-LP20 is as shown in SEQ ID NO: 1 (Sequence Identity Number 1). According to the present invention, the Pucurbita pepo active polypeptide Nacrein-LP20 has characteristics of strong DPPH free radical and hydroxyl free radical removing ability and excellent antioxidant activity, can significantly promote HaCaT cell proliferation in the high glucose environment, and can promote migration and repair of HaCaT cells in the high glucose environment; the traditional Chinese medicine composition has a remarkable healing promoting effect on full-cortical resection wound surfaces of normal rats and diabetic rats.

The invention discloses a raw amylolytic enzyme mutant as well as an expression strain and application thereof. According to the present invention, alpha-amylase AmyZ1 from Pontibacillus sp.ZY is adopted as a starting enzyme, a substrate binding subsite is determined through molecular docking, and site-directed mutagenesis is performed on residues at a + 1 site and at a 199 site so as to obtain the mutant enzyme L199F with high glucose yield; when the mutant enzyme is used in an industrial sugar manufacturing process, corn raw starch is used as a substrate, and the DE value can reach 35% after liquefaction for 2 h and is 1.44 times that of a starting enzyme; after saccharification for 18 hours, the DE value can reach 99%, which is 5 hours earlier than that of the starting enzyme. Therefore, the mutant enzyme has relatively high potential application value in the field of sugar industry taking corn raw starch as a substrate.

The invention relates to the technical field of industrial microorganisms, and particularly discloses a yeast strain and application thereof. The invention provides clavipora lusitaniae YJHT233, which is obtained through space mutation breeding, can tolerate 9% of alcohol, can tolerate an acid environment with the lowest pH value of 2.5, can tolerate a 12% high NaCl system, a 55% high glucose system and a 44 DEG C high temperature environment, and has excellent ester production capacity. The strain is used for brewing rice-flavor liquor or yellow wine, the total content of ester substances in the obtained product is greatly increased, the content of main volatile ester substances such as ethyl acetate, ethyl butyrate, isoamyl acetate, ethyl caprylate and ethyl lactate is remarkably increased, the whole flavor is coordinated and pleasant, and the fruit fragrance is rich and rich in layers.

The invention relates to the technical field of biological pharmacy, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell inflammation. The recombinant protein DEL-1 has a remarkable inhibition effect on pancreatic beta cell inflammatory response induced by high glucose and high fat. Experiments show that in an islet beta cell inflammation model constructed by combining high glucose with palmitic acid, DEL-1 can significantly reduce the expression level of inflammatory factors such as IL-1beta, IL-6, TNF-alpha and the like. The DEL-1 is proved to have a definite effect of resisting pancreatic beta cell inflammation.

The invention provides a blood glucose concentration prediction optimization method, and relates to the technical field of data prediction. Comprising the following steps: S1, constructing an original data set for blood glucose concentration prediction, performing unit root test on the original data set, if the original data is stable, performing no processing, otherwise, performing first-order difference processing on the non-stable original data; obtaining a first data set; s2, performing normalization processing on the first data set, and performing smoothing processing on normalized characteristic values through correlation coefficients to obtain an input data set for blood glucose concentration prediction; s3, converting the input data set into a supervised input data set consisting of an input prediction point # imgabs0 # and an output prediction value # imgabs1 # according to a time sequence; and S4, inputting the supervised input data set into a PECO-BP-based blood glucose prediction model, and outputting a real-time predicted value of the blood glucose concentration. The PECO-BP-based blood glucose prediction model provided by the invention can improve the prediction precision and prediction sensitivity of the blood glucose concentration.

The invention provides a bismuth-based heterogeneous material for promoting healing of diabetic wounds and a preparation method and application thereof. The bismuth-based heterogeneous material comprises a bismuth-based porphyrin metal organic framework, and the surface of the bismuth-based porphyrin metal organic framework is modified with Au-Pt nanoparticles. According to the bismuth-based heterogeneous material disclosed by the invention, microenvironments of bacterial infection, high glucose, active oxygen damage, inflammatory disorder, pH rise and oxygen deficit of diabetic wounds are improved through multiple antibacterial effects and enzyme catalysis effects, so that the healing of the diabetic wounds is promoted.

The invention provides a non-invasive continuous blood glucose monitoring system based on radio frequency wave and biosensor fusion, and aims at solving the problems of pain and inconvenience of a traditional fingertip blood sampling monitoring method. The system core comprises a radio frequency wave transmitter which is used for monitoring the glucose level in blood in real time through interaction of radio frequency waves with specific frequency and glucose molecules; meanwhile, biosensor technologies such as electrocardiogram (ECG) and photoplethysmogram (PPG) are combined, physiological signals are analyzed to estimate the blood glucose level, and the monitoring accuracy and reliability are improved. Besides, the developed wearable device integrates a radio frequency wave transmitter and a biosensor, can continuously monitor the blood glucose level, and transmits data to a mobile device or a medical center in a wireless mode. And a deep learning algorithm is adopted to perform fusion processing on the multi-modal signals, so that the accuracy of blood glucose monitoring is further improved. The system is non-invasive, real-time and accurate, improves the compliance and life quality of diabetic patients, and is of great significance to management and treatment of diabetes.

The invention discloses a cane molasses extract with a blood sugar reducing effect as well as a preparation method and application thereof, and belongs to the field of functional foods. According to the invention, cane molasses is subjected to dissolution, centrifugation, ultrafiltration impurity removal, desalination and nanofiltration concentration, and is mixed with calcium chloride, so that the cane molasses extract with the effect of reducing blood sugar is prepared. Experimental results prove that the cane molasses extract prepared by the invention has the characteristics of low glycemic index (GI), carbohydrate digestive enzyme inhibition, high temperature resistance, long-term storage resistance and the like, can also effectively repair pancreas and liver injury and regulate intestinal flora, and has a comprehensive hypoglycemic effect. The food with low glycemic index is prepared on the basis of the high sucrose carrier for the first time, and the food has sweet taste and the function of reducing blood sugar. The invention provides a new raw material scheme for the preparation of dietary supplement food and hypoglycemic drugs for hyperglycemia people, and has prominent practical application value and wide application prospect.

The invention belongs to the technical field of biological medicine, and particularly relates to application of CNPY2 as a new target in diagnosis and treatment of diabetic nephropathy. The invention provides a biomarker CNPY2 gene or CNPY2 protein for auxiliary diagnosis of diabetic nephropathy for the first time. The expression of the CNPY2 in the renal tubule of a DN patient is up-regulated, the expression of the CNPY2 in the renal tubule of a db / db mouse is up-regulated, and the expression of the CNPY2 in an HK-2 cell subjected to in-vitro high-glucose culture is up-regulated; therefore, the CNPY2 can be used as an auxiliary diagnosis index of the diabetic nephropathy for auxiliary diagnosis of the diabetic nephropathy. The invention also provides a kit for auxiliary diagnosis of diabetic nephropathy. The kit contains a detection reagent of the CNPY2 gene or the coded protein. The invention also finds that by knocking down the adeno-associated virus through the CNPY2 and inhibiting the expression or activity of the CNPY2 through the specific small interfering RNA of the adeno-associated virus, the pathological injury of the renal tubules of db / db mice can be obviously improved, the integrity of MAM in the renal tubule epithelial cells is improved, and the ferroptosis, ERS and mitochondrial injury of the renal tubule epithelial cells are alleviated; therefore, the CNPY2 can be used as a drug, a drug target or a target gene in gene therapy, and is applied to prevention, alleviation or / and treatment of diabetic nephropathy.

The invention discloses construction of a bifunctional carbon-based solid acid catalyst and application of the bifunctional carbon-based solid acid catalyst in efficiently converting glucose into 5-HMF (5-hydroxymethylfurfural) in a biphase system. The difunctional carbon-based solid acid catalyst is prepared by taking alkali lignin as a carbon source, potassium chloride as a salt template, and p-toluenesulfonic acid and aluminum nitrate nonahydrate as Browster acid and Lewis acid catalytic active site precursors respectively. The bifunctional carbon-based solid acid catalyst has rich oxygen-containing functional groups, a graded porous structure and a proper ratio of Browster acid active sites to Lewis acid active sites. In addition, the catalyst shows excellent catalytic activity in a two-phase system, can obtain high glucose conversion rate and 5-HMF yield under relatively mild reaction conditions, and has good cycle stability. According to the novel difunctional carbon-based solid acid catalytic reaction system disclosed by the invention, the purpose of efficiently catalyzing conversion of glucose into 5-HMF is achieved.

The utility model discloses a detection circuit for a blood glucose testing device, the blood glucose testing device comprises a test paper reaction unit and a processing unit, and the test paper reaction unit comprises an impedance testing electrode pair and a current testing electrode pair; the processing unit comprises an impedance detection module, a current detection module and a potential tracking module, the impedance detection module is connected with the impedance test electrode pair and used for testing the impedance of the blood glucose sample, the impedance detection module comprises a signal generator, and the signal generator is used for applying an alternating current signal or a direct current signal to the impedance test electrode pair; the current detection module and the potential tracking module are respectively connected with the current test electrode pair, the current detection module can apply excitation voltage to the current test electrode pair for testing the current of the blood glucose sample, and after the excitation voltage is disconnected, the potential tracking module can test the attenuation potential of the current test electrode pair. The attenuation potential is measured, and the attenuation potential can be used as one of blood glucose calibration parameters, so that the blood glucose detection accuracy can be improved.

The invention belongs to the technical field of assisted reproduction, and particularly relates to a glucose slow-release structure used in an embryo in-vitro culture solution, a preparation process and a use method. The glucose slow-release structure comprises at least one inner layer containing glucose and a biodegradable material outer layer wrapping the inner layer, and the biodegradable material outer layer comprises a matrix with a plurality of micropores and at least one sealing material layer used for sealing pores of the micropores. According to the invention, gradient release from low sugar in the cleavage stage to high sugar in the blastocyst stage is realized, midway liquid change or artificial sugar supplement is not needed, the operation is obviously simplified, and pollution and mechanical stress risks are reduced.

The application discloses a kind of glucose oxidase sensors based on modified multi-walled carbon nanotube modification, it is related to glucose oxidase sensor technical field, including the following steps: (1) modified multi-walled carbon nanotube preparation;(2) glassy carbon electrode is carried out surface polishing treatment;(3) obtain modified multi-walled carbon nanotube dispersion;(4) obtain glucose oxidase liquid;(5) glucose glucose oxidase liquid impregnation electrode;(6) using Nafion solution covers electrode;The sensor obtained after the electrode is modified by introducing modified multi-walled carbon nanotube in the application, not only has higher glucose detection sensitivity, but also has excellent stability.

The invention discloses application of selazinomethyl ether and a pharmaceutical composition thereof in preparation of a medicine for preventing or treating brain injury. The invention provides the application of selazine methyl ether in preparing the medicine for preventing or treating the brain injury for the first time, and selazine methyl ether has a remarkable effect in preventing or treating the brain injury, especially cerebral arterial thrombosis and the brain injury caused by hemorrhagic transformation of the cerebral arterial thrombosis. And cerebral injury caused by cerebral arterial thrombosis and hemorrhagic transformation can be obviously relieved. According to the application disclosed by the invention, the sefoazinomethyl ether has the effects of remarkably reducing the cerebral infarction area and behavioral scoring under the condition of middle cerebral artery occlusion; the selobezine methyl ether has the effects of remarkably reducing the hemorrhage area, hemorrhage score and behavioral score under acute high glucose and middle cerebral artery occlusion; the pharmaceutical composition containing selazine methyl ether can become a novel drug for preventing or treating brain injury, and can be used for treating various cerebrovascular diseases including cerebral arterial thrombosis and hemorrhagic transformation of cerebral arterial thrombosis.

This disclosure relates to ribosomal remodeling due to high glucose conditions. In some embodiments, translation of proteins in pancreatic beta-cells is altered based on the ribosomal remodeling. Means of increasing the percentage of large ribosomal subunit protein P1 (RPLP1) associated with ribosomes and / or decreasing the percentage of soluble RPLP1 in a cell to counteract effects of high glucose conditions in diabetes are disclosed.

The invention discloses an in-vivo blood glucose monitoring system based on microgel response characteristics, which is characterized by improving a microgel synthesis process, accurately characterizing physical properties and response characteristics of a material, optimizing the design of an implanted microgel sensor and constructing an electromagnetic detection module based on dielectric constant measurement. Accurate, real-time and continuous monitoring of the in-vivo blood glucose level is achieved. The system overcomes the problems of large trauma, discontinuous data, insufficient long-term stability, high cost and the like of a traditional blood drawing method by utilizing the remarkable volume and dielectric constant change of microgel under the conditions of low blood sugar and high blood sugar, and has the remarkable advantages of high sensitivity, quick response and long-term stability; a brand new technical scheme is provided for precise management of metabolic diseases such as diabetes, and the technical scheme also has a wide application prospect in other biomedical monitoring fields.

The present invention discloses a polyporus badius polysaccharide and its preparation method and application, belonging to the technical field of polysaccharide extraction. The polyporus badius polysaccharide (PPP-0A) includes galactose, fucose, glucose, mannose and xylose, and the molar ratios are 62.26%, 16.96%, 15.23%, 4.68% and 0.87% respectively. The present invention uses techniques such as methylation, scanning electron microscopy, thermogravimetric analysis, nuclear magnetic resonance and atomic force microscopy to determine the structural characteristics of PPP-0A, analyze its composition and properties, and its inhibitory effects on the activities of α-glucosidase and α-amylase. In addition, an in vitro HepG2 cell model induced by high blood glucose and high insulin levels was used to study the hypoglycemic effect of PPP-0A. The present invention provides a theoretical basis for clarifying the relationship between the hypoglycemic activity of PPP-0A and its hypoglycemic effect on type 2 diabetic mice.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The present invention discloses applications and methods of Leuconostoc mesenteroides, relating to the field of microbial technology. Leuconostoc mesenteroides can be used to prepare phytic acid and improve non-alcoholic fatty liver disease, increased liver weight, elevated blood lipids, elevated blood sugar, elevated serum lipopolysaccharide levels, elevated serum insulin levels, inflammatory responses, and elevated triglyceride levels in the liver caused by a high-fat, high-sugar diet, and inhibit the release of the pro-inflammatory cytokine lipopolysaccharide.

The invention relates to the technical field of medicines, in particular to application of a recombinant protein DEL-1 in preparation of a medicine for resisting pancreatic beta cell senescence. Within the concentration range of 400-1000 ng / ml, the DEL-1 can reduce the high glucose and high fat induced pancreatic beta cell SA-beta-Gal positive rate by 39.5% or above, and the anti-aging effect is remarkable.

An auricular stimulation device having surface electrodes biased towards each other, and offset from one another, is provided. The stimulation device can be positioned about the ear of a patient with each of the electrodes overlaying auricular ear tissue containing innervation supplied by an auricular branch of the vagus nerve. The electrodes transcutaneously stimulate the auricular branch. Also provided is a method of treating a patient using the auricular stimulation device. The stimulation device can be used for treating patients with conditions such as high blood pressure, depression, high blood glucose level, and tinnitus. Also provided is a diagnostic and therapeutic system having the auricular stimulation device, a smart device and a monitoring device. The smart device controls the auricular stimulation device based on biomarker information received from the monitoring device; and on information related to the patient, such as age, musculoskeletal stability, etc.; and / or on user input.

Disclosed is recombinant Escherichia coli for producing L-tyrosine and application thereof, and belongs to the technical fields of genetic engineering and bioengineering. According to the present disclosure, genes aroP and tyrP are knocked out, expresses the endogenous gene yddG of E. coli, then heterologously expresses fpk from Bifidobacterium adolescentis, expresses the endogenous genes ppsA and tktA of E. coli, and then expresses aroGfbr and tyrAfbr. Knocking out tyrR, trpE and pheA, so that the synthesis flux of L-tyrosine is increased. Finally, an endogenous gene poxB is knocked out to realize stable fermentation performance at high glucose concentration.

The present invention relates to a biocompatible tattoo ink that changes color in response to varying glucose levels in the bloodstream, providing a continuous monitoring method for individuals with diabetes. The ink contains glucose-sensitive agents that cause the tattoo to change from green (normal glucose levels) to red (high glucose levels) or blue (low glucose levels). Additionally, the ink shifts back to green when blood glucose returns to normal from either hyperglycemia or hypoglycemia. This provides a real-time visual indicator of glucose levels and enables users to monitor their health without additional equipment.

The invention belongs to the technical field of biology, and relates to agrobacterium capable of resisting high glucose and producing curdlan at high yield and application of the agrobacterium in curdlan production. The Agrobacterium is radioactive Agrobacterium sp. LQC24G-08, and is preserved in the China Center for Type Culture Collection on February 24, 2025, the address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: M 2025287. The Agrobacterium has the advantages that the Agrobacterium is used for culturing the Agrobacterium; when the agrobacterium provided by the invention is used for fermentation production of curdlan, the fermentation process is simple, the fermentation yield of the curdlan is higher, and the agrobacterium has high sugar tolerance and is beneficial to industrial application.

Provided are various embodiments relating to a GLP1R agonist or a dual agonist that specifically binds canine, feline, and / or equine GLP1R, or Glucagon receptor / G1PR. Such agonists can be used alone or in combination in methods to treat canine, feline, and / or equine metabolic disorders, such as high glucose, obesity, osteoarthritis, improved cardiovascular outcomes, and for the extension of healthy aging.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD), is a condition characterized by the accumulation of fat in the liver of individuals with no alcohol consumption, and at least one cardiometabolic risk factor (overweight / obesity, high blood pressure, high blood sugar, high triglycerides levels, low HDL-C levels). The inventors demonstrated that Rab30 silencing improve metabolic dysfunction–associated steatotic liver disease (MASLD). The present invention relates to a method for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) in a subject in need thereof comprising the administration of a therapeutically effective amount of an inhibitor of Rab30.

The invention relates to an Escherichia coli recombinant strain for producing 3-dehydroshikimic acid, a construction method and application, and belongs to the field of enzyme engineering.The Escherichia coli recombinant strain TP06 serves as an original strain, shikimic acid dehydrogenase AroE genes are knocked out, endogenous ppsA, transaldolase talA and tktA genes of Escherichia coli are overexpressed, prerequisite supply of shikimic acid ways is increased, and the yield of 3-dehydroshikimic acid is increased. The synthesis flux of DHS is improved; an aroG mutant aroGFBR from escherichia coli is expressed, and the 3-deoxy-D-arabinoheptanoic acid-7-phosphate synthetase which is subjected to feedback inhibition by aromatic amino acid is relieved by the mutant. Then, a key gene poxB in a byproduct synthesis route is knocked out through a Red homologous recombination gene knockout technology, acetic acid accumulation in the fermentation process is reduced, high-glucose-concentration fermentation is achieved, and the yield of DHS is further increased. And finally, the engineering strain realizes higher DHS production through fed-batch fermentation.

The application discloses a kind of recombinant escherichia coli for producing L-tyrosine and application, belong to genetic engineering and bioengineering technical field.The application knocks out aroP and tyrP gene, expresses the yddG gene of escherichia coli endogenous to modify the aromatic amino acid transport system of escherichia coli, then heterologous expression comes from bifidobacterium fpk and expresses the ppsA and tktA gene of escherichia coli endogenous to increase the precursor supply of shikimic acid pathway, again through the anti feedback gene expression aroG and tyrA 3-deoxy-D-arabino-heptulosonic acid-7-phosphate synthetase, branch acid mutase and prephenate dehydrogenase are removed feedback inhibition, increase the carbon flux of shikimic acid pathway.Knock out tyrR gene removes the repression of TyrR protein to shikimic acid pathway key enzyme, again knock out trpE and pheA gene to block partial side reaction of shikimic acid pathway, so that the synthesis flux of L-tyrosine increases.Finally knock out endogenous poxB gene to realize the modification of acetic acid pathway, realizes the stable fermentation performance of high glucose concentration.

The invention discloses stevia fiber healthy sugar suitable for diabetics to eat and a preparation method of the stevia fiber healthy sugar, and relates to the technical field of food. The healthy sugar disclosed by the invention is prepared from the following raw materials in parts by weight: 1-30 parts of stevioside and 70-99 parts of dietary fibers. An element for enhancing sweetness comes from a stevia rebaudiana aqueous extract stevioside, the natural dietary fiber is used as a carrier to simulate the overall characteristics of cane sugar, and the use of the carrier creates a synergistic effect in taste, so that the product is more like cane sugar, and the bad flavor of stevioside is also masked; the bad flavor of stevioside is masked by adopting the natural method, so that the quality of the product is very stable, and the shelf life can be up to 24 months; meanwhile, the dietary fiber in the product has the effects of reducing blood sugar, helping digestion, prebiotics and the like, and is very beneficial to the treatment of patients with hyperglycemia and diabetes mellitus.